![]() |
IATDMCT PresidentDario Cattaneo |
Academic commitments
Awards
Publications / scientific activities
Main clinical/research activities
I envisage the future of the IATDMCT society as the key player for the tailoring of drug therapy in increasingly complicated patients (elderly, with comorbidities and heavy polypharmacy) at the bedside, taking advantage from the presence of active members with excellences and expertise in several fields. The accomplishment of this task requires, however, a day-by-day, two-way strict collaboration with specialists from different medical disciplines. In other words, the labs need to meet/match the clinics!
![]() |
IATDMCT President-ElectJan Willem Alffenaar |
Memberships: IATDMCT, NVZA (Dutch Society of Hospital Pharmacists), NvKFB (Dutch association for Clinical Pharmacology and biopharmaceutics), KNMP (Royal Dutch Society of Pharmacy), The International Union Against Tuberculosis and Lung Disease, ESCMID (European Society of Microbiology and Infectious Diseases, ASID (Australasian Society of Infectious Diseases, ISAP (International Society of Anti-Infective Pharmacology), ASM (American Society for Microbiology)
Committees: member of Human Ethics Research Committee, member of Scientific Advisory Committee, member of Clinical Trials Advisory Committee, member of Drug Committee WSLHD, Global Tuberculosis Network – Clinical Pharmacology Committee (chair)
IATDMCT activities: editorial board member TDM, past vice chair/past chair Anti-infective committee, past vice chair/past chair/current vice chair of Alternative Sampling Committee, Local Scientific advisory Committee IATDMCT Conference 2015, recipient of Victor Armstrong Young Investigator award 2015
Professional appointments: editorial board member Journal of Mass Spectrometry & Advances in the Clinical Lab, associate editor International Journal of Tuberculosis and Lung Disease, Expert advisor on Clinical Pharmacology of TB drugs WHO-ERS-ECDC Concilium
Number of publications: 301 publications in peer reviewed journals
Invited speaker: > 80 invited lectures on national and international conferences
To influence patient-centred therapeutic drug monitoring and clinical toxicology at a global level, the IATDMCT should embrace international collaborative multidisciplinary research, thereby delivering high impact research. By developing an interactive regional training, education and professional development program, focused on early career researchers and clinicians, the IATDMCT will be positioned to attract creative and inspiring leaders of the future to deliver its promise to patients and their families to improve their health and well-being.
![]() |
IATDMCT SecretaryFlorian Lemaitre |
![]() |
IATDMCT TreasurerMaria Shipkova |
Academic Degrees:
Professional Registrations:
Professional Society Memberships:
Publications:
Stipends and Awards:
Varia:
![]() |
IATDMCT Past PresidentYusuke Tanigawara |
Education & Certification
Other academic and professional appointments
![]() |
Director of EducationBirgit Koch |
Publications:
Activities in IATDMCT:
Executive Committee:
Committees:
Memberships:
Editorial boards:
Professional appointments:
Invited talks 2019-2021:
![]() |
Director of EducationDebbie Marriott |
Professional Societies:
![]() |
Director of EducationChristoph Stove |
Teaching activities
Responsible for the following courses:
Research activities (overview & selection):
Member of scientific societies:
Service Activities (external):
![]() |
IATDMCT CouncillorRyuji Kato |
Dr. Ryuji Kato is an Associate Professor of Cardiovascular Pharmacotherapy and Toxicology at Osaka University of Pharmaceutical Sciences, Osaka, Japan. He completed his master’s degree in 2000 at Osaka University and began his career as a pharmacist at the Yokkaichi Social Insurance Hospital (Mie, Japan). He then moved to Osaka University of Pharmaceutical Sciences as an Assistant Professor. In 2008, he received his PhD in Pharmaceutical Sciences.
His research interests primarily include the appropriate use of pharmaceutical products. He has conducted extensive research on pharmacokinetics, drug-drug interactions (chelation complexes, drug-drug interactions on cytochrome P450 or via transporters), and serious adverse side effects (QT prolongation, drug induced liver injury, interstitial pneumonia, Stevens-Johnson syndrome, and toxic epidermal necrolysis).
He is the author or co-author of approximately 70 peer-reviewed manuscripts. Dr. Kato is a member of the following academic societies: International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Japanese Society of Therapeutic Drug Monitoring (JSTDM), Society of Toxicology (SOT), Pharmaceutical Society of Japan, and Japanese Society of Nephrology and Pharmacotherapy (JJNP). He has been a member of IATDMCT Communication Committee since 2015 and is an inspector for JSTDM.
![]() |
IATDMCT CouncillorMichael Neely |
Post-Graduate Training:
Publications:
Speaking engagements:
IATDMCT:
American College of Clinical Pharmacology:
![]() |
IATDMCT CouncillorJean-Baptiste Woillard |
Research interest:
Awards:
Invited conference and oral communications:
Positions in learned societies:
Membership in learned societies:
Consensus conferences:
Number of publications:
![]() |
IATDMCT CouncillorMiao Yan |
Employment
Education & Certification
Professional Activities